By Colin Kellaher

Regeneron Pharmaceuticals Inc. and Sanofi SA on Friday said a Phase 3 study of their blockbuster eczema drug Dupixent in the chronic skin condition prurigo nodularis met its primary and all secondary endpoints.

The companies said Dupixent significantly reduced itch at 12 weeks, while nearly three times as many Dupixent patients experienced reductions in both itch and skin lesions at 24 weeks compared to placebo.

Regeneron and Sanofi said prurigo nodularis is the sixth disease where Dupixent has shown positive Phase 3 results, adding that they plan to begin regulatory submissions next year.

Regeneron, of Tarrytown, N.Y., created Dupixent and markets it jointly in the U.S. with France's Sanofi under a 2007 collaboration agreement. Sanofi markets the product internationally.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

October 22, 2021 06:24 ET (10:24 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024 Click aqui para mais gráficos Sanofi.
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024 Click aqui para mais gráficos Sanofi.